TA1
Thymosin alpha-1
A 28-amino-acid peptide, acetylated at the N-terminus, corresponding to the N-terminal region of prothymosin alpha. It is a defined single sequence, unlike the thymus extracts it is often shelved beside. The published work describes activity at Toll-like receptors on antigen-presenting cells.
Thymosin alpha-1 has 50 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 14,247 planned or enrolled participants across the 47 studies that published a figure. No FDA-approved product contains Thymosin alpha-1. 96 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Thymosin alpha-1; the registry search is fuzzy, so every match is re-checked. None of this says whether Thymosin alpha-1 works or is safe.
FDA status
Research only
Human studies
50
Furthest phase
Phase 4
Papers, 10 yr
96
Readership
54
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Reached phase 3 or 4, not approved
50
Registered human studies
Phase 4
Furthest phase reached
14,247
Planned or enrolled participants, across 47 studies that published a figure
None
No FDA-approved product contains it
63 loose registry matches were checked and 50 confirmed — 13 named something else and were discarded. We count a study only when Thymosin alpha-1 is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Thymosin alpha-1 is, and what it has been studied for
Thymosin alpha-1 is classified by ChEMBL as a protein.
Across 50 registered trials, it has been studied in Thymalfasin, Hepatitis B, Chronic, Non-small Cell Lung Cancer and Radiotherapy. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Sun Yat-sen University and SciClone Pharmaceuticals among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Thymosin alpha-1 reached Phase 4 across 50 registered trials.
No FDA-approved product contains Thymosin alpha-1. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Thymosin alpha-1?
Papers published each year that name Thymosin alpha-1 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 9 | 0 | Yes |
| 2018 | 14 | 0 | Yes |
| 2019 | 11 | 0 | Yes |
| 2020 | 16 | 0 | Yes |
| 2021 | 10 | 0 | Yes |
| 2022 | 6 | 0 | Yes |
| 2023 | 13 | 1 | Yes |
| 2024 | 8 | 0 | Yes |
| 2025 | 8 | 0 | Yes |
| 2026 | 6 | 0 | No |
96 papers and 1 registered trials between 2017 and 2026. A paper counts when “Thymosin alpha-1” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Thymosin alpha-1
96 indexed papers name Thymosin alpha-1 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Thymosin alpha-1
- Aging and Thymosin Alpha-1
- Thymosin alpha 1: A comprehensive review of the literature
- Thymosin alpha-1 treatment in chronic hepatitis B
- Thymosin α-1 in cancer therapy: Immunoregulation and potential applications
- Thymosin alpha 1 treatment for patients with sepsis
- Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis
- Clinical applications of thymosin alpha-1
Collected 2026-08-02from PubMed, phrase-matched on “Thymosin alpha-1” in title and abstract. Run the same search.
About Thymosin alpha-1
A 28-amino-acid peptide, acetylated at the N-terminus, corresponding to the N-terminal region of prothymosin alpha. It is a defined single sequence, unlike the thymus extracts it is often shelved beside. The published work describes activity at Toll-like receptors on antigen-presenting cells.
- Also known as
- Thymalfasin · Talpha1
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.